Immunai, which uses AI to analyze the human immune system, raises $60M Series A led by Schusterman Foundation and others (Kyle Wiggers/VentureBeat)

Immunai 60m Series – A New Startup That’s Reprogramming the Immune System For the Better

A new startup, Immunai, has recently emerged, with the aim of advancing research in the human immune system. The two founders are Noam Solomon and Luis Voloch. They are both engineers and scientists who have developed technology to analyse the human immune system. The company is looking to raise funding from a number of sources, including VCs, philanthropists and other private investors. The founders hope that the company’s work will lead to improved health outcomes and reduced healthcare costs.

Noam Solomon and Luis Voloch

Founded by Noam Solomon and Luis Voloch, Immunai is an AI powered company that’s reprogramming the immune system for the better. Its mission is to speed up immunotherapy drug development by mapping the human immune system cell by cell. It is also home to the largest clinical immunological data set in the world, which is referred to as AMICA.

Its motto is “Mapping the Human Immune System One Cell at a Time.” The company is headquartered in New York and has 70 members spread across 15 countries. It’s also got its own wet lab in New York City.

As the name suggests, the company is using machine learning and AI algorithms to map out the human immune system. It has created an impressive database that contains thousands of samples. It uses machine learning to find and identify new biomarkers for diseases, suggest new treatments, and help academics understand what experimental therapies do to the immune system.

The company has partnered with some of the leading names in the field, including Harvard, Mass General, Baylor, UPenn, and Memorial Sloan Kettering. It is also working with several Fortune 100 pharma companies, which is no small feat. Its most recent funding round includes a $215 million Series B, led by Koch Disruptive Technologies, and a $60 million Series A, led by TLV Partners, Catalio Capital Management, and the Duquesne Family Office.

In its efforts to repurpose the immune system, the company has produced terabytes of data from blood samples. The company has also created a proprietary database that maps these to different cell types. The most obvious benefit is that it allows researchers to tease out the best targets to attack. It is estimated that 90 percent of drugs that reach the clinic don’t receive regulatory approval.

The company has produced the best and most comprehensive single cell data set on the planet. The company’s other main claim to fame is the ability to tell you what’s in cell therapy products. With this information, they are in a position to accelerate the development of new drugs, thus saving lives.

Funding sources

Immunai is a New York and Tel Aviv-based biotech startup leveraging machine learning and data analytics to advance immunotherapies. Its technology is used to map and analyze the human immune system at a single cell level. It also has a proprietary Annotated Multi-omic Immune Cell Atlas (AMICA), a database that combines data from hundreds of immune cells to map data to hundreds of cell states.

Using its technology, Immunai’s team is able to profile cells at unprecedented depth and record data in terabytes. This technology is able to provide insight on cell populations post-treatment, synergistic effects with immunotherapies, and mechanism of action.

Its unique edge is the ability to combine the most voluminous set of data in the industry. Its machine learning platform uses this technology to deliver analytics at scale. As a result, the company is able to provide a better understanding of the human immune system, which can help biopharmas identify potential drug targets.

The company’s AI and machine learning technology is already being used to help boost the performance of existing immunotherapies. Its AMICA technology is used to perform simulations, harmonize data from multiple cohorts around the world, and explain the mechanism of action, toxicity, and other characteristics of various immunotherapies.

It has recently announced a partnership with 10x Genomics, which will help the company build a larger data set, expand its clinical capabilities, and facilitate the discovery of new therapies. It has also formed several partnerships with academic institutions and biotech companies. It plans to double its headcount this year.

The company has been able to leverage its technology to map the human immune system at a single cell layer, which is a first in the field. It has also established the world’s largest database for single cell immunity characteristics.

The company’s recent funding round of $60 million will allow it to increase its headcount and expand its capabilities. It will also fund the development of new immunotherapies and drug combinations. It will use the funds to extend its functional genomics capabilities and to expand its AMICA database, which will enable it to answer key questions in immuno-oncology and cell therapy.

Technology used to analyze the human immune system

The human immune system is a complex network of cells and proteins that protects our body from harmful pathogens. However, diseases and autoimmune disorders can occur if the immune system is compromised. In order to understand and combat these issues, researchers need to analyze the human immune system. In recent years, technological advances have given researchers the ability to make maps of the distribution of immune cells at the single-cell level. This research will aid in identifying areas where the immune system needs to improve its function.

One of the most important advances in immunology research is multi-parametric flow cytometry. This technology allows scientists to analyze dozens of analytes at the same time. It has revolutionized vaccine research and testing candidate vaccines. Aside from determining the concentration of several proteins, these tests also give researchers insight into the functional activities of multiple cells.

Another technological advancement is CRISPR, a genome editing method that allows scientists to edit genetic material inside living cells. This method has been used successfully by Jennifer Doudna and Michael Marson to edit the genes of immune cells. This type of genome editing can be used to edit thousands of nucleotides at once. These advances enable precise genome editing and have the potential to lead to immune-based therapies that can be clinically manufactured.

The human immune system is composed of two types of responses: innate and adaptive. In the innate response, the immune system detects and destroys foreign material, while the adaptive response consists of a cell-mediated response triggered by activated B cells and T cells. These responses are regulated by a number of signaling pathways. These include the TLR, JAK/STAT, and NFKB pathways.

Another important characteristic of the immune system is its capacity to generate antibodies. This gives the immune system the ability to fight against cancer and infectious diseases. In addition, this capability allows the body to develop a memory of microbes. This memory allows the body to respond more rapidly to the same microbe.

The immune system keeps a record of every germ it has defeated. This information can be used to better prevent future infections.

Visit our site: Infowars

Leave a Reply

Your email address will not be published.